Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02848781 · ClinicalTrials.gov registry record · NA

Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial

A NA study, sponsored by University of Arizona.

Completed
Registry status
NA
Development phase
180
Enrollment target

NCT02848781: Completed NA study, sponsored by University of Arizona.

NCT02848781 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 180 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02848781, a NA study, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
NA
Development phase
180 participants
Enrollment target

Study Summary

The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Catheter ablation is a procedure used to eliminate (damage) the heart cells causing the arrhythmia. Patients eligible for this may benefit from an ablation procedure in addition to an ICD to treat their VT condition or risk of developing VT. This study aims to show that treating VT with catheter ablation, if performed preemptively at the time of ICD implantation, will reduce subsequent recurrent VT, ICD shocks, and lead to improved survival.

Primary Outcome

The primary endpoint is a composite.

Interventions

  • DEVICE Implantable Cardioverter Defibrillator (ICD)
  • PROCEDURE Catheter Ablation

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2015-11-30
Est. Completion 2021-03-29
Phase NA
University of Arizona

349 total trials

What the finished NCT02848781 record still lists

NCT02848781 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which Implantable Cardioverter Defibrillator (ICD) is the first listed.

NCT02848781 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02848781 about?

NCT02848781 is a clinical study titled "Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial". The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Cathet...

What is the current status of trial NCT02848781?

This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2015-11-30. Estimated completion is 2021-03-29.

What interventions are being tested in trial NCT02848781?

The interventions under investigation include: Implantable Cardioverter Defibrillator (ICD) (DEVICE), Catheter Ablation (PROCEDURE).

Who is sponsoring clinical trial NCT02848781?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02848781's enrollment target sits among peer trials

180 586th of 2000 higher than 1,397 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02848781, the US trial registry maintained by the National Library of Medicine. NCT02848781 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.